Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|October 31, 2019

Integra Offers Clear Advantage Product for NGS Library Preparation

Clear Advantage is a product line of multichannel reagent reservoirs to be used for creating a next-gen sequencing library

Integra Biosciences now offers Clear Advantage, a product line of multichannel reagent reservoirs that, along with its Voyager product line of adjustable-tip spacing electronic multichannel pipettes, helps ensure efficient and reliable pipetting for the preparation of next-generation sequencing (NGS) libraries. The products help reduce experimental costs, according to the company.

The Clear Advantage reagent reservoir portfolio saves money and space by using disposable inserts that fit into reusable bases. The reservoirs are offered in 10-mL, 25-mL, and 100-mL sizes, now available with the SureFlo system, which minimizes dead volumes. The SureFlo system works through a series of tiny channels that enable pipette tips to sit on the bottom of a reservoir without sealing or creating a vacuum. This ensures the smooth flow of reagents by preventing liquid from “popping” into tips, filters, or pipettes-an issue that can lead to cross-contamination, inaccurate results, and increased pipette maintenance. Each reservoir also has a specially formulated inert, hydrophilic treatment that prevents liquid from pooling. Thus, the reservoir offers the lowest dead volumes on the market, with all reservoirs offering dead volumes of less than 50 μl.

SureFlo is made up of polystyrene and polypropylene reservoirs, appropriate for use with expensive reagents, such as polymerase chain reaction master mixes.

Source: Integra Biosciences


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.